Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series

2011 ◽  
Vol 93 (6) ◽  
pp. 782-786 ◽  
Author(s):  
Shanthi Sivendran ◽  
Harold Harvey ◽  
Allan Lipton ◽  
Joseph Drabick
Keyword(s):  
Zoledronic Acid ◽  
Langerhans Cell Histiocytosis ◽  
Case Series ◽  
Langerhans Cell ◽  
Bone Lesions

scholarly journals BISPHOSPHONATES IN LANGERHANS CELL HISTIOCYTOSIS: AN INTERNATIONAL RETROSPECTIVE CASE SERIES

2016 ◽  
Vol 8 ◽  
pp. 2016033 ◽  
Author(s):  
Deepak Chellapandian ◽  
Polyzois Makras ◽  
Gregory Kaltsas ◽  
Cor Van den Bos ◽  
Lamia Naccache ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Langerhans Cell Histiocytosis ◽  
Case Series ◽  
Initial Response ◽  
Langerhans Cell ◽  
Bone Lesions ◽  
International Studies ◽  
First Line ◽  
Retrospective Case ◽  
Multisystem Disease

Background: Bone is the most common organ of involvement in patients with Langerhans cell histiocytosis (LCH), which is often painful and associated with significant morbidity from pathological fractures. Current first-line treatments include chemotherapy and steroids that are effective but often associated with adverse effects, whereas the disease may reactivate despite an initial response to first-line agents. Bisphosphonates are osteoclast inhibitors that have shown to be helpful in treating bone lesions of LCH. To date, there are no large international studies to describe their role in treating bone lesions of LCH. Method: We conducted a multicenter retrospective review of 13 patients with histologically proven LCH, who had received bisphosphonates either at diagnosis or at disease reactivation. Results: Ten patients (77%) had a single system bone disease, and 3 (23%) had bone lesions as part of multisystem disease. Median follow-up time post-bisphosphonate therapy was 4.6 years (range, 0.8 to 8.2 years). Treatment with bisphosphonates was associated with significant pain relief in almost all patients. Twelve  (92%) achieved resolution of active bone lesions, and 10 out of them had no active disease for a median of 3.5 years (range, 0.8 to 5 years). One patient did not respond. No major adverse effects were reported in this series.  Conclusion: Bisphosphonates are well-tolerated drugs that can significantly improve bone pain and induce remission in active bone LCH. Future prospective studies evaluating the role of bisphosphonates in LCH are warranted.

Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis

2008 ◽  
Vol 27 (1) ◽  
pp. 110-113 ◽  
Author(s):  
Liliana Montella ◽  
Carmela Merola ◽  
Geraldina Merola ◽  
Luigi Petillo ◽  
Giovannella Palmieri
Keyword(s):  
Zoledronic Acid ◽  
Langerhans Cell Histiocytosis ◽  
Langerhans Cell ◽  
Bone Lesions

scholarly journals Periodontal manifestations of Langerhans cell histiocytosis: a systematic review

2021 ◽  
Author(s):  
Julia C. Difloe-Geisert ◽  
Selina A. Bernauer ◽  
Noémie Schneeberger ◽  
Michael M. Bornstein ◽  
Clemens Walter
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Case Series ◽  
Langerhans Cell ◽  
Treatment Modalities ◽  
Bone Lesions ◽  
Bias Assessment ◽  
Initial Symptoms ◽  
Treatment Measures ◽  
Oral Symptoms ◽  
Tooth Extractions

Abstract Objectives To explore the evidence of periodontal manifestations and treatment modalities in patients with Langerhans cell histiocytosis (LCH). Material and methods A systematic literature search was performed and the criteria for PRISMA and risk of bias assessment were applied. Human clinical studies (≥10 patients) presenting patients with LCH and periodontal findings were considered for inclusion. Results From 298 titles identified, six case series with a total of 1278 patients suffering from LCH were included. In these studies, oral symptoms were reported in a frequency ranging from 10 to 100%. Overall, in 216 patients (17%), oral symptoms were observed. Out of these patients, 49–100% demonstrated periodontal symptoms. The most common oral findings were pain, swelling, tooth loss/mobility, and bone lesions. Specific periodontal findings comprised varying frequencies of gingival ulcerations, increased pocket depths, and gingival bleeding. Treatment measures constituted of surgical curettage of bone lesions, soft tissue excision and/or tooth extractions, radiotherapy, systemic chemotherapy, or a combination of these approaches. Healing without recurrence of oral lesions was reported in most of the cases. Conclusions The available evidence on periodontal manifestations in LCH patients is heterogeneous. Several oral and periodontal findings were reported and may occur as initial symptoms and/or at later stages of the disease. Clinical relevance The dentist should be aware of possible oral involvement of systemic diseases such as LCH, and these manifestations may mimic periodontal disease.

scholarly journals Pulmonary Langerhans Cell Histiocytosis with Lytic Bone Involvement in an Adult Smoker: Regression following Smoking Cessation

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
B. Routy ◽  
J. Hoang ◽  
J. Gruber
Keyword(s):  
Smoking Cessation ◽  
Cigarette Smoking ◽  
Langerhans Cell Histiocytosis ◽  
Case Series ◽  
Bone Destruction ◽  
Bone Diseases ◽  
Langerhans Cell ◽  
Braf V600e ◽  
Bone Lesions ◽  
Pulmonary Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by the proliferation and dissemination of histiocytes. These in turn may cause symptoms ranging from isolated, infiltrative lesions to severe multisystem disease. Pulmonary Langerhans cell histiocytosis (PLCH) presents as a localized polyclonal proliferation of Langerhans cells in the lungs causing bilateral cysts and fibrosis. In adults, this rare condition is considered a reactive process associated with cigarette smoking. Recently, clonal proliferation has been reported with the presence of BRAF V600E oncogenic mutation in a subset of PLCH patients. Spontaneous resolution was described; however, based on case series, smoking cessation remains the most effective way to achieve complete remission and prevent long term complications related to tobacco. Herein, we report the case of an adult woman with biopsy-proven PLCH presenting with thoracic (T8) vertebral bone destruction. Both the lung and the bone diseases regressed following smoking cessation, representing a rare case of synchronous disseminated PCLH with bone localization. This observation underscores the contribution of cigarette smoking as a systemic trigger of both pulmonary and extrapulmonary bone lesions. A review of similar cases in the literature is also presented.

scholarly journals Initial Symptoms of Langerhans Cell Histiocytosis: A Case Series

2019 ◽  
Vol 6 ◽  
pp. 2333794X1985737 ◽  
Author(s):  
Yukari Atsumi ◽  
Yuya Saito ◽  
Hiroshi Hataya ◽  
Yuki Yuza
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Medical Center ◽  
Bone Lesion ◽  
Case Series ◽  
Langerhans Cell ◽  
Long Bone ◽  
Bone Lesions ◽  
Initial Symptom ◽  
Initial Symptoms ◽  
Skull Lesion

Langerhans cell histiocytosis (LCH) is a rare childhood hematopoietic disease, and hence, there are few reports summarizing the course leading to the diagnosis. We described the initial symptoms and the clinical course of LCH. We carried out a retrospective review of charts from a single medical center, and 21 patients with the diagnosis of LCH were enrolled. The initial symptoms of 16 cases were caused by bone lesions; of these cases, there were 8 instances of soft tissue swelling as the initial symptom (38%) and 8 instances of bone pain without swelling (38%). Among the cases of bone lesion, 4 of 6 cases of skull lesion were painless while all vertebral body lesions and long bone lesions were accompanied by pain. LCH bone lesions caused various symptoms depending on the site of the lesion and this makes the diagnosis difficult. A detailed physical examination and imaging studies are recommended for early diagnosis.

scholarly journals Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2209-2209 ◽  
Author(s):  
Deepak Chellapandian ◽  
Polyzois Makras ◽  
Gregory Kaltsas ◽  
Cor van den Bos ◽  
Anne-Sophie Carret ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Langerhans Cell Histiocytosis ◽  
Bone Pain ◽  
Conflicts Of Interest ◽  
Treatment Strategies ◽  
Bisphosphonate Therapy ◽  
Langerhans Cell ◽  
Bone Lesions ◽  
Multisystem Disease ◽  
Pathologic Fractures

Abstract Introduction: Langerhans cell histiocytosis (LCH) is a monoclonal disorder characterized by proliferation and accumulation of atypical Langerhans cells and in up to 55% of all cases somatic mutations in BRAF proves to be the driver. Although uncommon, it is potentially fatal and carries significant morbidity. Bone involvement in LCH can be destructive, painful and often associated with pathologic fractures. There is no consensus in the treatment strategies for bone LCH which could vary from simple curettage with biopsy and/or intralesional steroids to more toxic systemic chemotherapy. However, the number of treatments for this disease is limited and other options need to be explored. Bisphosphonates are osteoclast inhibitors that can target certain osteoclast markers expressed by the multinucleated giant cells in the skin, bone and lymph nodes LCH lesions and can potentially be used to alleviate bone pain and possibly control the progression of disease activity. Purpose: To evaluate the efficacy and safety of bisphosphonates in treating bone LCH and extra-osseous disease. Methods: An international multicenter retrospective chart review was conducted in children and adults with LCH who received bisphosphonates between 1995 and 2014. Results: Eighteen patients were identified from 4 centers. All received bisphosphonates therapy either at diagnosis or at ≥ 1st reactivation. Median age at start of bisphosphonates was 23.7 years (range 5.7-38.3 years), and median follow-up time post-bisphosphonate therapy was 2.8 years (range 0.9-5.0 years). Patients had either single system bone disease or bone lesions as part of their multisystem disease. Patients were treated with different bisphosphonates with majority received zoledronic acid (n=10), followed by pamidronate (n=4) and alendronate (n= 3); one patient received both pamidronate and zoledronic acid. All patients reported significant reduction in pain to either no or mild pain after administration of bisphosphonates. Thirteen of 18 patients (72%) achieved complete remission (CR) in their bone lesions, including lesions in skin (n=1), lung (n=1) and pituitary (n=1); 2 had partial response and 3 had no response. Among the 13 CR patients, 12 had no active disease for a median of 4.1 years (range 2.8 - 5.1 years) and 1 developed radiographic neurodegeneration after 2 years. Bisphosphonate therapy was well tolerated by all patients with no major toxicity. Progression-free survival (PFS) was 75 ± 11% at 3 years, with a trend favoring better PFS (P=0.24) in patients with no or first reactivation compared with those having ≥ 2 reactivations. Conclusion: Bisphosphonates is a well-tolerated medication that can significantly improve bone pain in patients with bone LCH, and may even be effective in treating extra-osseous disease. A prospective randomized trial evaluating the role of bisphosphonates in multifocal bone LCH is warranted. Disclosures No relevant conflicts of interest to declare.

scholarly journals Paediatric Langerhans Cell Histiocytosis Disease: Long-Term Sequelae in the Hypothalamic Endocrine System

2021 ◽  
pp. 1-9
Author(s):  
Elisa Vaiani ◽  
Guido Felizzia ◽  
Fabiana Lubieniecki ◽  
Jorge Braier ◽  
Alicia Belgorosky
Keyword(s):  
Anterior Pituitary ◽  
Langerhans Cell Histiocytosis ◽  
Endocrine System ◽  
Langerhans Cell ◽  
Hormone Deficiency ◽  
Bone Lesions ◽  
Pituitary Hormone ◽  
Multisystem Disease ◽  
Anterior Pituitary Hormone

Langerhans cell histiocytosis (LCH) is a disorder of the mononuclear phagocyte system that can affect almost any organ and system. The most common central nervous system (CNS) manifestation in LCH is the infiltration of the hypothalamic-pituitary region leading to destruction and neurodegeneration of CNS tissue. The latter causes the most frequent endocrinological manifestation, that is, central diabetes insipidus (CDI), and less often anterior pituitary hormone deficiency (APD). The reported incidence of CDI is estimated between 11.5 and 24% and is considered a risk factor for neurodegenerative disease and APD. Three risk factors for development of CDI are recognized in the majority of the studies: (1) multisystem disease, (2) the occurrence of reactivations or active disease for a prolonged period, and (3) the presence of craniofacial bone lesions. Since CDI may occur as the first manifestation of LCH, differential diagnosis of malignant diseases like germ cell tumours must be made. APD is almost always associated with CDI and can appear several years after the diagnosis of CDI. Growth hormone is the most commonly affected anterior pituitary hormone. Despite significant advances in the knowledge of LCH in recent years, little progress has been made in preventing long-term sequelae such as those affecting the hypothalamic-pituitary system.

A Review of Noninfectious Diseases Masquerading as Acute Mastoiditis

2021 ◽  
pp. 019459982110641
Author(s):  
Kevin Wong ◽  
Annie E. Arrighi-Allisan ◽  
Caleb J. Fan ◽  
George B. Wanna ◽  
Maura K. Cosetti ◽  
...  
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Inflammatory Diseases ◽  
Case Series ◽  
Diagnostic Algorithm ◽  
Langerhans Cell ◽  
Myelogenous Leukemia ◽  
Common Disease ◽  
Acute Mastoiditis ◽  
Significant Group ◽  
Presenting Symptoms

Objective Acute mastoiditis is commonly attributed to infection. Rarely do clinicians encounter cases that do not respond to traditional antibiotics or surgical management. The goal of this study was to systematically review the literature to characterize diseases masquerading as acute infectious mastoiditis. Data Sources PubMed, Embase, and Scopus. Review Methods A systematic review was performed to identify all publications that reported on diseases with presentations mimicking acute mastoiditis, defined as postauricular redness, swelling, and tenderness. We included clinical prospective studies, retrospective studies, and case series/reports. Exclusion criteria included non-English articles, letters/commentaries, abstracts, and review articles. Results Out of 3339 results, 35 studies met final inclusion criteria. In children, 11 diseases were reported to mimic mastoiditis, including solid tumors, hematologic diseases, and autoimmune/inflammatory diseases. The most common disease in children was Langerhans cell histiocytosis, followed by rhabdomyosarcoma and acute myelogenous leukemia. In adults, 8 additional diseases were reported. The most common disease in adults was squamous cell carcinoma, followed by nasopharyngeal carcinoma and Langerhans cell histiocytosis. Presenting symptoms are reviewed, as well as characteristic radiographic, laboratory, and intraoperative features that may assist with diagnosis. A diagnostic algorithm for atypical cases of acute mastoiditis is proposed. Conclusion A small but significant group of diseases in children and adults can mimic acute mastoiditis. In such cases, history and examination alone may be insufficient to reach a diagnosis, and further investigation may be necessary. Otolaryngologists should always be mindful of the possibility that noninfectious pathologies may present with a constellation of symptoms similar to mastoiditis.

scholarly journals Langerhans Cell Histiocytosis with Isolated Central Diabetes Insipidus, Low Grade Fever and Sellar Erosion

2021 ◽  
Author(s):  
İclal Okur ◽  
Hasan Ari ◽  
Semra Çetinkaya ◽  
Betül Emine Derinkuyu ◽  
Gizem Çağlar ◽  
...  
Keyword(s):  
Diabetes Insipidus ◽  
Langerhans Cell Histiocytosis ◽  
Bone Structure ◽  
Sella Turcica ◽  
Langerhans Cell ◽  
Central Diabetes Insipidus ◽  
Bone Lesions ◽  
Warning Sign ◽  
Low Grade ◽  
First Case

Langerhans cell histiocytosis (LCH) is a rare disease of the monocyte-macrophage system. Although it is known that bone involvement is seen very frequently in cases with LCH, our case is the first case with a lytic-destructive lesion in the bone structure forming sella turcica. A 4-year-old, 5-month-old male patient who applied to our outpatient clinic was diagnosed with Langerhans cell histiocytosis in further examination after the diagnosis of central diabetes insipidus (CDI) was made. On cranial magnetic resonance imaging (MRI), widespread lytic-destructive bone lesions were observed in the bone structure forming the sella (sphenoid bone), sellar destruction not previously described in the literature. Sellar erosion has not been reported before in cases diagnosed with LCH in the literature. The presence of low-grade fever in a patient presenting with isolated CDI is a warning sign for the diagnosis of LCH.

Sign in / Sign up

Export Citation Format

Share Document